News Room

An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer New Jersey’s research-based biopharmaceutical industry is constantly developing new cures and treatments that benefit

$350 billion goes to middlemen Trenton, January 11, 2022 ― An update to an important study demonstrates that pharmacy benefit managers (PBMs) and other middlemen

An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer and Christopher P. Molineaux, President and Chief Executive Officer of Life Sciences Pennsylvania

Kenneth Frazier, executive chairman, and Robert Davis, chief executive officer of Merck; Alex Gorsky, chairman and chief executive officer, and Joaquin Duato, incoming chief executive

This legislation poses the danger of decimating the workforces and economies of Delaware, New Jersey and Pennsylvania.   August 30, 2021 ― Thirty business leaders